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Reduced nitric oxide (NO) bioavailability and increased oxidative stress are major factors mediating ischemia/reperfusion
(I/R) injury. Tetrahydrobiopterin (BH4) is an essential cofactor of endothelial NO synthase (eNOS) to produce NO, whereas
dihydrobiopterin (BH2) can shift the eNOS product proﬁle from NO to superoxide, which is further converted to hydrogen
peroxide (H2O2) and cause I/R injury. The eﬀects of BH4 and BH2 on oxidative stress and postreperfused cardiac functions
were examined in ex vivo myocardial and in vivo femoral I (20min)/R (45min) models. In femoral I/R, BH4 increased NO and
decreased H2O2 releases relative to saline control, and these eﬀects correlated with improved postreperfused cardiac function. By
contrast, BH2 decreased NO release relative to the saline control, but increased H2O2 release similar to the saline control, and
these eﬀects correlated with compromised postreperfused cardiac function. In conclusion, these results suggest that promoting
eNOS coupling to produce NO and decrease H2O2 may be a key mechanism to restore postreperfused organ function during early
reperfusion.
1.Introduction
The further damage caused by reperfusion following
ischemia (I/R) has been a crucial event to attenuate in order
topreservemoretissueororganfunction[1,2].Understand-
ing mechanisms related to I/R injury in clinical cases involv-
ing myocardial infarction, coronary bypass/angioplasty, and
organ transplantation provides a basis to develop new targets
of intervention to attenuate the pathophysiological process.
Reduced nitric oxide (NO) bioavailability and increased
oxidative stress are major factors mediating I/R injury [3].
It has been shown that endothelium-derived NO is abruptly
decreased within 5 minutes of reperfusion that results in
endothelial dysfunction in myocardial I/R (MI/R) injury
[3]. Endothelial dysfunction serves as a trigger to initiate
the upregulation of endothelial cellular adhesion molecules
to promote polymorphonuclear leukocyte (PMN) adher-
ence and inﬁltration [3–5]. Subsequently, the transmigrated
PMNs release cytotoxic substances such as superoxide (SO)
radicals to directly injure the myocardium and cause cardiac
contractile dysfunction [4, 6].
It is well known that vascular NO is produced by
endothelial NO synthase (eNOS) by converting L-arginine
to L-citrulline in the presence of molecular oxygen. Tetrahy-
drobiopterin (BH4) is an essential cofactor of eNOS to aid
in the coupling between L-arginine and the heme site within
the oxygenasedomain of eNOS [7]. Underthis coupledstate,
eNOS produces NO to facilitate normal blood ﬂow and to
maintain an antiinﬂammatory and antithrombotic vascular
endothelial surface [8]. By contrast, dihydrobiopterin (BH2),
an oxidized form of BH4, can cause uncoupling between
L-arginine and eNOS. Under this condition, eNOS utilizes
molecular oxygen as the substrate in the absence of L-
arginine to generate SO instead of NO [9–11]. SO is further
converted into hydrogen peroxide (H2O2)b ys u p e r o x i d e
dismutase. Moreover, incomplete oxidative phosphorylation2 Advances in Pharmacological Sciences
in dysfunctional mitochondria in murine endothelial cells
can facilitate additional oxidation of BH4 to BH2,t h u s
increasing the BH2 to BH4 ratio to further promote eNOS
uncoupling [12, 13]. With this regard, eNOS uncoupling
may induce NO insuﬃciency, but also contribute to the
oxidative stress under various pathological conditions, such
as I/R. Previous studies evaluated that increasing eNOS
activity with PKC epsilon activator resulted in compromised
postreperfused heart function, whereas decreasing eNOS
activity with PKC epsilon inhibitor resulted in restoration
of postreperfused cardiac function associated with decreased
H2O2 release in rat femoral artery/vein subjected to I/R
[12]. By contrast, a nonselective NOS inhibitor, NG-nitro-
L-arginine methyl ester (L-NAME), does not appreciably
inhibit SO release from NOS and consequently is not
associated with improvement of cardiac function in many
MI/R models [11, 14].
Regarding BH4, previous studies have shown that BH4
given prior to myocardial ischemia signiﬁcantly restored
post-reperfusioncardiacfunctionintheisolatedperfusedrat
heart and enhanced nitrite levels in the coronary perfusate
[15]. Although, the potential opposing eﬀects of BH2 were
notinvestigatedintheYamashiroetal.study.Inaddition,the
role of BH4 or BH2 mediating eNOS coupling or uncoupling
exclusivelyduringtheearlyreperfusionhasnotbeenassessed
in real-time in vivo or ex vivo. This is clinically important in
that pretreatment may not be an option in clinical settings
whereas treatment during the early reperfusion would be
more practical and helpful to improve the organ function.
Therefore, in this study, BH4 was used during the early
reperfusion within 5 minutes to promote the eNOS coupled
state,whereasBH2 wasutilizedtofurthermaintaintheeNOS
uncoupled state. The following hypotheses were tested.
Firstly,theeﬀectsofBH4 orBH2 onvascularNOreleasewere
tested by directly measuring NO release from nonischemic
rataorticsegmentsandfromfemoralarteries/veinssubjected
to I/R in anesthetized rats. Secondly, the eﬀects of BH4
or BH2 on oxidative stress (i.e., H2O2)w e r er e c o r d e db y
directly measuring H2O2 release from femoral arteries/veins
subjected to I/R in anesthetized rats. Thirdly, the eﬀects of
BH4 or BH2 on postreperfused cardiac function and PMN
vascular adherence/inﬁltration were determined in a PMN-
induced MI/R injury animal model. Then L-NAME was
used to test if the cardioprotection and decreased PMN
adherence/inﬁltration provided by BH4 could be blocked to
indicate a NO mechanism involved in this cardioprotection.
2. Methods
2.1. In Vitro Measurement of NO Release from Rat Aortic
Segments. The Institutional Animal Care and Use Com-
mittee of Philadelphia College of Osteopathic Medicine
approved all animal protocols performed in this study. As
previously described, the isolated rat aortas were cut to 6-
7mm long (i.e., 10mg wet weight) after removal of adherent
fat and connective tissue. Then these aortic rings were cut
open and ﬁxed by pins with the endothelial surface facing
up in 24-well culture dishes containing 1mL oxygenated
Krebs’-Henselit (K-H) solution maintained at 37
◦C( i n
Table 1: The eﬀects of BH4 or BH2 on NO release from
nonischemic rat aortic segments.
Basal/Treatments NO release
(picomoles/mg tissue) Sample No.
Basal 2.28 ± 0.25 n = 17
Ach (5μM) 5.38 ±0.70
∗∗ n = 20
BH4 (1μM) 2.74 ± 0.16 n = 14
BH4 (10μM) 4.45 ± 0.43∗ n = 21
BH4 (20μM) 4.88 ±0.50
∗∗ n = 24
BH4 (40μM) 5.01 ±0.61
∗∗ n = 21
BH2 (50μM) 0.87 ±0.33## n = 21
BH2 (100μM) 0.86 ±0.23## n = 25
BH2 (200μM) 0.78 ±0.33## n = 14
Ach (5μM)+L-NAME
(800μM)
−0.59 ±0.38 n = 5
BH4 (10μM)+L-NAME
(800μM)
−1.14 ±0.48 n = 8
BH2 (100μM)+L-NAME
(800μM)
−1.70 ±0.34 n = 8
∗P<. 05, ∗∗P<. 01 compared to basal NO release; ##P<. 01 compared to
the eﬀects of BH4 on NO release.
mmol/L: 10.0 dextrose, 119.0 NaCl, 12.5 NaHCO3,2 . 5
CaCl2, 4.8 KCl, 1.2 KH2PO4,a n d1 . 2M g S O 4). The NO
release was measured using a calibrated NO meter (Iso-
NO; World Precision Instruments, Sarasota, FL) connected
to a polygraph internally shielded NO electrode [16]. Basal
rat aortic endothelial NO release was determined by the
diﬀerence of reading between a well containing only K-H
buﬀer and the well containing aortic tissue as in previous
studies [17]. After basal NO measurement, the eﬀects of
acetylcholine (Ach, 5μM) and BH4 (1–40μM) or BH2 (50–
200μM) were determined. Ach was used as a positive control
to assess the viability of the endothelium. Then 800μML -
NAME was added to the K-H buﬀer solution; the eﬀects of
Ach (5μM), BH4 (10μM), or BH2 (100μM) were reassessed
30 minutes later to evaluate if L-NAME could block NO
r e l e a s e .A l lm e a s u r e m e n t sw e r er e p o r t e di np i c o m o l e sp e r
milligram of aortic tissue. The number of trials for each
group was indicated in Table 1.
2.2. In Vivo Measurement of NO/H2O2 R e l e a s ef r o mR a t
Femoral Veins during Reperfusion. NO or H2O2 release was
measured from femoral veins in anesthetized rats, one
subjectedtoI/Randtheotherisanonischemicshamcontrol.
This rat femoral I/R model was based on the procedure
of Kuntscher et al. [18]. The NO or H2O2 microsensors
(100μm diameter) connected to a free radical analyzer
(Apollo 4000; World Precision Instruments, Sarasota, FL)
were inserted into a catheter and placed inside each femoral
vein as previously published [12]. Ischemia of femoral
circulation in one side would be induced by clamping the
femoral artery/vein for 20 minutes followed by 45 minutes
reperfusion via releasing the clamp, which was similar to
the MI/R time course. BH4 (6.5mg/kg, which corresponds
to about 250μM in the blood concentration), BH2 (2 orAdvances in Pharmacological Sciences 3
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Figure 1: Schematic diagram of the ischemia/reperfusion protocol in the isolated perfused rat heart model.
4mg/kg, which corresponds to about 100 or 200μM in the
blood concentration), or saline (for nondrug control group)
was applied through tail vein injection at the beginning
of reperfusion. The total volume of solution was 1mL
saline or drug mixed with saline. NO or H2O2 release was
continuously recorded and collected at 5 minutes intervals
during a 15-minute baseline period, 20-minute ischemia and
45-minute reperfusion. The changes in NO or H2O2 release
duringreperfusion(inpA)wereexpressedasrelativechanges
to baseline (initial). Thereafter, the values were converted
to the concentration of NO (nM) or H2O2 (μM) after
correction to the preexperimental calibration curve of NO
or H2O2 microsensors.
2.3. Isolated Rat Heart Preparation. After injecting pento-
barbital sodium (60mg/kg) and sodium heparin (1,000 U)
intraperitoneally(i.p.),heartswererapidlyexcisedfrommale
Sprague Dawley rats (275–325g, Ace Animals, Boyertown,
PA) [19]. Then the heart was subjected to retrograde
perfusion with a modiﬁed Krebs’ buﬀer composed of
17.0 dextrose, 120.0 NaCl, 25.0 NaHCO3,2 . 5C a C l 2,0 . 5
EDTA, 5.9 KCl, and 1.2 MgCl2 (in mmol/L, 37
◦C, pH of
7.3-7.4). Three side arms in the perfusion line proximal
to the heart inﬂow cannula, allowed perfusing BH4 or
BH2/plasma, PMNs, and L-NAME. Coronary ﬂow was
monitored by a ﬂowmeter (T106, Transonic Systems, Inc.,
Ithaca, NY). Left ventricular-developed pressure (LVDP,
deﬁned as left ventricular end-systolic pressure minus left
ventricular end-diastolic pressure) and the maximal rate
of LVDP (+dP/dtmax) were monitored using a pressure
transducer (SPR-524, Millar Instruments, Inc., Houston,
TX), which was positioned in the left ventricular cavity.
LVDP, +dP/dtmax, and coronary ﬂow were measured every
5 minutes for 15 minutes baseline recording; 20-minute
global ischemia was induced by stopping perfusion (i.e.,
turning stop-cock to oﬀ position) and 45-minute reperfu-
sion. The schematic protocol is shown in Figure 1.A l ld a t a
were recorded using a Powerlab Station acquisition system
(ADInstruments, Grand Junction, CO) in conjunction with
a computer (Gateway).
The isolated rat heart was cannulated via the aorta onto
a perfusion needle and was immersed in a water-jacketed
reservoir that contains 160mL of Krebs’ buﬀer maintained
at 37
◦C. The preload volume came from Krebs’ buﬀer
that ﬁlled the left ventricle upon insertion of the pressure
transducer catheter in the base of the left side of the heart.
Table 2: Experimental groups in observation of postreperfused
cardiac function from the isolated perfused rat heart.
Group Sham I/R I/R I/R+PMN I/R+PMN+L-
NAME
Control
(No Drug) n = 6 n = 7 n = 9
BH4 (1μM) n = 6
BH4 (5μM) n = 6
BH4 (10μM) n = 6 n = 7 n = 6 n = 6
BH2 (100μM) n = 4 n = 5 n = 7
We also used animals in the same weight range for all study
groupsandthereforethepreloadshouldbesimilaramongall
study groups as in previous studies [17, 19, 20]. The initial
baseline left ventricular end-diastolic pressure was between
4 – 8m m H gf o ra l lh e a r t si ne a c hs t u d yg r o u p .
2.4. Groups of Isolated Perfused Hearts. Table 2 indicates the
12 groups (control and treatment conditions) of isolated
perfused rat hearts used in the study. Three types of control
groups were used in the study based on the well-established
PMN-induced MI/R model [21]. (1) Sham hearts were not
subjected to ischemia and are not perfused with PMNs,
but they were perfused with 5mL of plasma (1mL/min)
at 35 minutes into perfusion (i.e., the same time point
that I/R hearts would be given 5mL of plasma: 15 minutes
of baseline recordings plus 20min ischemia). This group
was employed to show that cardiac function (i.e., LVDP
and +dP/dtmax) could be maintained throughout the 80-
minute protocol. (2) I/R hearts were subjected to 20 minutes
of ischemia/45 minutes of reperfusion, and were perfused
with 5mL of plasma (1mL/min) in the absence of PMNs
during the ﬁrst 5 minutes of reperfusion. This group was
employed to show that these hearts would recover to near
baseline valuesby theend of45-minute reperfusion.Twenty-
minute ischemia followed by 45-minute reperfusion would
stun the heart but was a form of reversible cell injury. (3)
I/R+PMN hearts were subjected to 20 minutes of ischemia
and were reperfused with PMNs (200 × 106,r e s u s p e n d e d
in 5mL Krebs’ buﬀer) and 5mL of plasma (1mL/min)
during the ﬁrst 5 minutes of reperfusion. This group was
employed to show that 20 minutes of ischemia followed by
45 minutes of reperfusion in the presence of PMNs resulted
inasustainedcardiaccontractiledysfunctionthroughoutthe4 Advances in Pharmacological Sciences
45-minute reperfusion period compared to initial baseline
values. Previous studies showed that sham hearts given
PMNs exhibited no changes from initial control values [19].
This result indicated that PMNs without ischemia were
not suﬃcient to induce sustained cardiac dysfunction. In
some sham and I/R hearts, BH4 (10μM) or BH2 (100μM)
was dissolved in plasma and infused at a rate of 1mL/min
for 5 minutes at 35 minutes into perfusion (sham) or at
the beginning of reperfusion. These groups were employed
to show that BH4 or BH2 did not exert a cardiotonic
or cardiodepressant eﬀect in sham or I/R settings at this
concentration. In some I/R+PMN hearts, diﬀerent doses of
BH4 (1–10μM) or BH2 (100μM) were infused at a rate
of 1mL/min for 5 minutes at the beginning of reperfusion
to test whether BH4 or BH2 m i g h te l i c i tc a r d i o p r o t e c t i v e
eﬀects. Furthermore, a NO synthase inhibitor, L-NAME
(50μM), was used throughout the 45 minutes of reperfusion
in some BH4-treated I/R+PMN hearts to determine if a
NO mechanism was involved in the cardioprotective eﬀect.
The dose of L-NAME (50μM) used in this study does not
signiﬁcantly aﬀect LVDP in sham hearts [22].
2.5. Isolation of Plasma. Blood was collected from the aorta
in citrate phosphate buﬀer (Sigma Chemical Co., St. Louis,
MO) just before isolation of the rat heart and centrifuged at
10,000g for 10 minutes at 4◦C. Then 5mL of plasma were
decanted and used for infusion for all cardiac perfusion
groups [19].
2.6. Isolation of PMNs. PMNs were prepared from Male
Sprague Dawley rats (350–400g, Ace Animals, Boyertown,
PA). After injection (i.p.) of 0.5% glycogen (Sigma Chemical
Co., St. Louis, MO) for 16–18hours, PMNs were harvested
by peritoneal lavage in 30mL of 0.9% NaCl and centrifuged
to remove the debris, as previously described [17]. The PMN
preparations were >90% pure and >95% viable, according
to microscopic analysis and exclusion of 0.3% trypan blue,
respectively.
2.7. Determination of PMN Vascular Adherence and Inﬁltra-
tionintotheCardiacTissue. Threeratheartsthatwereclosest
to the group mean for the cardiac function studies from each
group were used for histological analysis. The hearts were
dehydrated in graded ice-cold acetone washes (50–100%)
and embedded in plastic and sectioned into 2.5μms e r i a l
sections. Then sections were stained with hematoxylin and
eosin by previously established methods [17]. Under light
microscopy, 10 areas of each rat heart from the left ventricle
were counted for PMN vascular adherence and inﬁltration
into the heart tissue and expressed as adhered and total
PMNs/mm2.
2.8. Statistical Analysis. All data in the text and ﬁgures were
presented as means ± SEM. The data from more than two
groups were analyzed by ANOVA. The data from only two
groups were analyzed by student t-test. Probability values of
<.05 were considered to be statistically signiﬁcant.
3. Results
3.1. BH4 or BH2 on Endothelial NO Release. NO release from
rat nonischemic aortic endothelium was measured to deter-
mine the eﬀects of BH4 or BH2 on NO release. Moreover,
the dose-responses of BH4 and BH2 on NO release also
provide the optimal dose ranges for testing their eﬀects in
oxidative stress and postreperfused cardiac function during
I/R. As shown in Table 1,B H 4 dose dependently increased
NO release, whereas BH2 dose dependently decreased NO
release from aortic segments. The basal endothelial NO
release was 2.28 ± 0.25 picomoles NO/mg tissue. BH4
(10μM, 20μM, and 40μM) produced a signiﬁcant increase
in NO release above basal to 4.45 ± 0.43 (P<. 05), 4.88
± 0.50 (P<. 01), and 5.01 ± 0.61 (P<. 01) picomoles
NO/mgtissue,respectively.Bycontrast,BH2 (50μM,100μM
and 200μM) dose dependently decreased endothelial NO
release. The decreases in NO release by BH2 were signiﬁcant
from the increasing NO releases by BH4 (all P<. 01).
Ach (5μM) was used as a positive control in this assay
and stimulated the endothelium causing an increase to 5.38
± 0.70 picomoles NO/mg tissue (P<. 01). The NOS
inhibitor, L-NAME(800μM),se rv edasnegati v ec o ntr ol,and
signiﬁcantly blocked NO release from aortic endothelium in
presence of Ach and BH4.
3.2. Eﬀects of BH4 or BH2 on H2O2 R e l e a s ef r o mR a tF e m o r a l
Veins during Reperfusion. The femoral vein subjected to
I/R in saline control rats exhibited a signiﬁcant increase in
H2O2 release (i.e., up to 3.2μM) throughout reperfusion
compared to sham vein (Figure 2(a)). This data supports the
concept that oxidative stress is increased during reperfusion.
Furthermore,H2O2 releaseincreasedin2mg/kgBH2-treated
animals similar to saline control (Figure 2(b)) in that H2O2
release signiﬁcantly increased in the I/R limb relative to the
sham limb throughout the 45 minutes of reperfusion. H2O2
release increased in the saline and BH2-treated animals by
2.6μMa n d3 . 5μM, respectively during the ﬁrst 5 minutes
of reperfusion and remained elevated by 3.2μMa n d2 . 1μM,
respectively, by 45 minutes of reperfusion (Figure 2(b)). By
contrast, applying 6.5mg/kg BH4 at the start of reperfusion
decreasedH2O2 release(i.e.,downto0.84μM)inthefemoral
I/R vein during the whole 45 minutes of reperfusion which
was signiﬁcant at 45 minutes of reperfusion in comparison
with the saline control femoral I/R vein regarding the relative
diﬀerence in each of their sham femoral veins, respectively
(Figure 2(b)). These ﬁndings indicated that BH4 applied at
the beginning of reperfusion decreased the oxidative stress
during reperfusion, whereas BH2 administration was similar
to saline control and did not further increase the oxidative
stress.
3.3. Eﬀects of BH4 or BH2 on NO Release from Rat Femoral
Veins during Reperfusion. Compared to sham vein, the
femoral vein subjected to I/R in saline control rats exhibited
a slight increase in NO release for the ﬁrst 5 minutes of
reperfusion(i.e.,upto8.2nM),andthengraduallydecreased
for the rest of reperfusion (i.e., decreased by 6.6nM from
baseline) (Figure 3(a)). The initial increase may be due toAdvances in Pharmacological Sciences 5
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Figure 2: Measurement of H2O2 (μM) release from rat femoral
veins during reperfusion in the saline control group and BH4-o r
BH2-treated group. (a) H2O2 (μM) releases from rat sham and
I/R femoral veins during reperfusion in the saline control group.
Anesthetized rats were given saline via tail vein at the beginning of
reperfusion(n = 7).TherewasasigniﬁcantincreaseinH2O2 release
from I/R veins compared to sham veins during reperfusion. (∗∗P<
.01 from sham limb) (b) The relative diﬀerence in H2O2 release
between I/R and sham femoral veins in the saline control group
(n = 7), BH4 (6.5mg/kg) treated group (n = 5), and BH2 (2mg/kg)
treated group (n = 6). BH4 or BH2 was given via tail vein at
the beginning of reperfusion. BH4 treatment signiﬁcantly decreased
H2O2 release at 45-minute reperfusion compared to saline control.
(∗P<. 05 from saline control group).
the shear wall stress after restoration of blood ﬂow. Applying
4mg/kg BH 2 at the beginning of reperfusion signiﬁcantly
decreased NO release (i.e., decreased by 220nM) from
2 0m i n u t e st o4 5m i n u t e so fr e p e r f u s i o n( a l lP <. 01)
in comparison with the saline control femoral I/R vein
regardingtherelativediﬀerenceineachoftheirshamfemoral
veins, respectively (Figure 3(b)). By contrast, 6.5mg/kg BH4
showed a signiﬁcant increase in NO release from 20 minutes
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Figure 3: Measurement of NO (nM) release from rat femoral veins
during reperfusion in the saline control group and BH4-o rB H 2-
treated group. (a) NO (nM) releases from rat sham and I/R femoral
veins during reperfusion in the saline control group. Anesthetized
rats were given saline via tail vein at the beginning of reperfusion
(n = 6). There was a slight decrease in NO release from I/R veins
compared to sham veins after 20 minutes of reperfusion. (b) The
relative diﬀerence in NO release between I/R and sham femoral
veins in the saline control group (n = 6), BH4 (6.5mg/kg)-treated
group (n = 6), and BH2 (4mg/kg)-treated group (n = 5). BH4
or BH2 was given via tail vein at the beginning of reperfusion.
BH2 treatment signiﬁcantly decreased NO release from 20 minutes
and throughout the rest of reperfusion. BH4 treatment signiﬁcantly
increased NO release from 20 minutes to 45-minute reperfusion
compared to BH2 treatment. (∗P<. 05, ∗∗P<. 01 from saline
control group; #P<. 05,## P<. 01 from BH2-treated group).
(P<. 05) to 45 minutes reperfusion (P<. 01) (i.e.,
up to 268nM) comparing to BH2 treatment (Figure 3(b)).
This data indicated that BH2 applied at the beginning of
reperfusion signiﬁcantly decreased NO release during reper-
fusion, whereas BH4 administration signiﬁcantly increased
NO release compared to BH2 treatment.6 Advances in Pharmacological Sciences
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Figure 4: Time course of cardiac function parameters (LVDP)
from sham, I/R, I/R+PMN, I/R+PMN+BH4 (10μM), and
I/R+PMN+BH2 (100μM) groups. There was no signiﬁcant
diﬀerence in baseline values among these groups. The sham group
(n = 6) maintained the same LVDP throughout the 80 minutes
protocol. The I/R+PMN (n = 9) and I/R+PMN+BH2 (n = 7)
groups exhibited a signiﬁcant and sustained reduction in LVDP
during the 45 minutes of reperfusion compared to sham. I/R
(n = 7) and I/R+PMN+BH4 (n = 6) groups exhibited signiﬁcant
restoration of LVDP during the 45 minutes reperfusion compared
to I/R+PMN group. All values are expressed as mean ± SEM.
(∗P<. 05, from I/R+PMN values).
3.4. Cardiac Eﬀects of BH4 or BH2 on PMN-Induced MI/R
Injury. Diﬀerent doses of BH4 or BH2, were applied individ-
ually to the isolated PMN-induced MI/R hearts to determine
their eﬀects on postreperfused cardiac function. Figure 4
showsthetimecourseofcardiaccontractilefunction(LVDP)
for the sham, I/R, I/R+PMN, I/R+PMN+BH4 (10μM), and
I/R+PMN+BH2 (100μM) groups. It illustrates the changes
in LVDP during the 80-minute perfusion period. The hearts
in the sham group maintained LVDP throughout the entire
duration of the perfusion period (96 ± 3% of initial baseline
values). I/R group hearts experienced a minor depression in
LVDP (i.e., down to 79% of initial baseline) during the initial
5 minutes of reperfusion, but by the end of reperfusion they
had recovered to 100 ± 10% of initial baseline values. By
contrast, hearts in the I/R+PMN group exhibited sustained
cardiac contractile dysfunction, only recovering to 53 ± 7%
of initial baseline values at 45-minute reperfusion. However,
BH4 (10μM) given during early reperfusion (i.e., ﬁrst 5
minutes) signiﬁcantly increased LVDP at 30, 40, and 45
minutes postreperfusion compared to I/R+PMN hearts (all
P<. 05) and recovered to 85 ± 8% of initial baseline. By
contrast, LVDP time course in BH2 (100μM)-treated group
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Figure 5: Initial and ﬁnal LVDP expressed in mmHg from diﬀerent
experimental groups. Hearts were perfused in the presence or
absence of PMNs. PMNs induced a signiﬁcant decrease in LVDP,
which was attenuated by the BH4 (10μM), not by BH2 (100μM).
L-NAME (50μM) blocked the cardioprotective eﬀect of BH4
treatment. All values are expressed as mean ± SEM. Numbers
of hearts are at the bottom of the bars. All drugs are in μM
concentrations. (∗∗P<. 01 from ﬁnal I/R+PMN values; NS, not
signiﬁcant compared to initial LVDP values).
was similar to that of I/R+PMN group (Figure 4). This data
suggests that BH4 treatment, not BH2 treatment, provided
signiﬁcant restoration in postreperfused LVDP.
Figures 5 and 6 showed the initial and ﬁnal values for
LVDP and +dP/dtmax from the control and diﬀerent treated
groups, respectively. There was no signiﬁcant diﬀerence
between the initial baseline values of all the groups studied.
There was also no signiﬁcant diﬀerence between the initial
and ﬁnal values of LVDP and +dP/dtmax for the sham
and I/R groups. In order to establish whether the BH4
or BH2 produced any direct inotropic eﬀects on cardiac
contractile function, sham and I/R hearts were perfused with
BH4 (10μM) or BH2 (100μM). The BH4 (10μM) or BH2
(100μM) treated sham and I/R hearts maintained a similar
cardiac function with respect to initial and ﬁnal LVDP and
+dP/dtmax, indicating that BH4 (10μM) or BH2 (100μM)
has no direct eﬀect on cardiac contractile function, even in
the setting of I/R without PMNs (data not shown).
However, I/R+PMN hearts only recovered to 53 ± 7%
of initial LVDP and 45 ± 7% of initial +dP/dtmax at 45
minutes post-reperfusion, both were signiﬁcantly lower than
initial baselines (Figures 5 and 6,b o t hP<. 01). This
result suggests that PMNs are principally responsible for the
sustained cardiac contractile dysfunction in this model of
MI/R. We have previously shown that the amount of PMNs
used in this model does not elicit cardiodepressant eﬀects in
sham hearts [19]. Collectively, these data indicate that the
combination of 20-minute ischemia followed by 45-minuteAdvances in Pharmacological Sciences 7
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Figure 6: Initial and ﬁnal +dP/dtmax expressed in mmHg/s from
diﬀerent experimental groups. Hearts were perfused in the presence
or absence of PMNs. PMNs induced a signiﬁcant decrease in
+dP/dtmax. Neither BH4 (10μM) nor BH2 (100μM) treatment
signiﬁcantly improved +dP/dtmax compared to I/R+PMN hearts.
All values are expressed as mean ± SEM. Numbers of hearts are at
thebottomofthebars.AlldrugsareinμMconcentrations.(NS,not
signiﬁcant compared to initial LVDP values).
reperfusion in the presence of PMNs is required to sustain
cardiac contractile dysfunction.
To test the eﬀect of BH4 on the PMN-induced post I/R
cardiac dysfunction, we applied this drug during the ﬁrst
5 minutes of reperfusion. BH4 exerted a dose-dependent
eﬀect on restoring postreperfused LVDP and +dP/dtmax. 1
and 5μMB H 4 treated I/R+PMN hearts ﬁnally recovered to
62 ± 9% and 61 ± 5% of initial LVDP, respectively, and
both were not signiﬁcantly diﬀerent from the ﬁnal values
of the I/R+PMN group (Figure 5). However, 10μMB H 4
exhibited signiﬁcant restoration in ﬁnal LVDP (85 ± 8% of
initial baseline) compared to that of I/R+PMN hearts (53
± 7% of initial baseline). By contrast, ﬁnal +dP/dtmax in 1,
5, and 10μMB H 4-treated I/R+PMN hearts were 55 ± 8%,
52 ± 3%, and 71 ± 7% of initial values, respectively, but
were not signiﬁcantly diﬀerent from the ﬁnal +dP/dtmax of
the I/R+PMN hearts (Figure 6). This data suggests that BH4
treatment during the early reperfusion can partially improve
post I/R cardiac contractile function.
On the other hand, application of BH2 (100μM) during
theﬁrst5minutesofreperfusiondidnotrestorepostreperfu-
sion cardiac contractile function in the presence of activated
PMNs. The I/R+PMN+BH2 (100μM) hearts recovered to
64 ± 4% and 56 ± 3% for LVDP and +dP/dtmax of initial
baseline at 45-minute postreperfusion, respectively. These
values were not signiﬁcantly diﬀerent from the ﬁnal values
of I/R+PMN control group (Figures 5 and 6). Moreover, the
cardiac function in BH2-treated animals was not diﬀerent
from I/R+PMN control hearts at any time point during the
reperfusion. This data suggests that BH2 treatment exhibited
the similar compromised postreperfused cardiac function as
the I/R+PMN control group.
3.5. Eﬀects of L-NAME on Cardioprotective Eﬀects of BH4.
To further determine if a NO mechanism is involved
in the cardioprotection of BH4 (10μM) application dur-
ing reperfusion, a NOS inhibitor, L-NAME (50μM), was
perfused throughout the 45-minute reperfusion. Previous
studies have shown that L-NAME given by itself during
reperfusion is not associated with cardioprotection [23]. The
cardioprotective eﬀects of BH4 (10μM) were blocked by L-
NAME suggesting that a NO mechanism was principally
responsibleformediatingthecardioprotectiveeﬀectsofBH4.
The ﬁnal LVDP and +dP/dtmax values in this group of hearts
were only 67 ± 3% and 58 ± 3% of the initial baseline,
respectively, and were not signiﬁcantly diﬀerent from the
ﬁnal values of the IR+PMN group (Figures 5 and 6).
3.6. Eﬀects of BH4 or BH2 on Postreperfused PMNs
Adherence/Inﬁltration. The inﬁltration of PMNs into the
myocardium within the 45-minute reperfusion period is
closely correlated with the cardiac injury associated with
I/R in this model. Therefore, PMN vascular adherence and
myocardial inﬁltration were determined foreachexperimen-
tal group. The representative PMN coronary vascular adher-
ence and transmigration from I/R+PMN and I/R+PMN+
BH4 (10μM) groups were shown by light microscopy under
20x, 40x, and 100x magniﬁcation (Figure 7). Arrowheads
indicate PMN adherence to the coronary vascular endothe-
lium, while arrows indicate PMNs that have inﬁltrated into
the myocardium. I/R+PMN+BH4 (10μM) hearts displayed
a considerable reduction in PMN vascular adherence and
tissue inﬁltration compared to I/R+PMN hearts.
The total and adhered intravascular PMNs from dif-
ferent experimental groups are shown in Figure 8. Sham
and I/R hearts exhibited very few vascular adhered and
transmigrated PMNs in the postreperfused heart tissue,
which represents only resident PMNs. However, I/R+PMN
hearts exhibited a signiﬁcantly increased total intravascular
and inﬁltrated PMNs (208PMNs/mm2 in I/R+PMN ver-
sus 20PMNs/mm2 in sham), as well as vascular adhered
PMNs (71PMNs/mm2 in I/R+PMN versus <2PMNs/mm 2
in sham). Similarly, BH2-treated hearts also showed signif-
icantly higher total (208PMNs/mm2) and vascular adhered
PMNs (73PMNs/mm2). By contrast, BH4 treated hearts
exhibited a dose-dependent decrease in total and vascular
adhered PMNs. The I/R+PMN+BH4 (10μM) hearts showed
signiﬁcantly less adhered PMNs (34PMNs/mm2) and total
PMNs (109PMNs/mm2) compared to those of I/R+PMN
hearts (both P<. 01). Furthermore, L-NAME blocked the
attenuation of total intravascular and inﬁltrated PMNs by
BH4 application during reperfusion (Figure 8).
4. Discussion
4.1. Summary of Major Findings. The major ﬁndings of this
study were as follows. (1) BH4 promoted NO release from
vascular endothelium in a dose-dependent manner, whereas8 Advances in Pharmacological Sciences
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Figure 7:Lightmicroscopyphotographofhematoxylinandeosin-stainedrathearttissuefromI/R+PMNandI/R+PMN+BH4 (10μM).(a)–
(c), I/R+PMN heart illustrated enhanced PMN coronary vascular adherence and tissue inﬁltration ((a): 20x; (b): 40x; (c): 100x). (d)–(f),
I/R+PMN+BH4 (10μM) heart exhibited a reduction in PMN coronary vascular adherence and tissue inﬁltration compared with I/R+PMN
((d): 20x; (e): 40x; (f): 100x). Arrows indicate inﬁltrated PMN and arrowheads indicate PMN adherence to coronary vasculature. Scale bar,
50μm.
BH2 decreased NO release in nonischemic rat aortic seg-
ments. (2) The increased oxidative stress (i.e., H2O2) during
reperfusion was signiﬁcantly decreased by BH4 (6.5 mg/kg)
in femoral I/R veins in vivo. (3) BH2 (4mg/kg) applied at the
beginning of reperfusion signiﬁcantly decreased NO release
during reperfusion, whereas BH4 (6.5mg/kg) signiﬁcantly
increased NO release compared to BH2 treatment in femoral
I/R veins in vivo. (4) BH4 (10μM), not BH2 (100μM)
treated I/R+PMN hearts, exerted signiﬁcant restoration in
LVDP, which was associated with signiﬁcant attenuation of
intravascular PMN adherence/inﬁltration in postreperfused
myocardium. (5) The cardioprotective eﬀects of BH4 on
cardiac contractile function and inﬁltrated/adhered PMNs
were blocked by L-NAME.
4.2. Contribution of BH4 to eNOS Coupling and BH2 to
eNOS Uncoupling. It is well known that BH4 is an essential
cofactor of eNOS to produce NO by maintaining eNOS in
the coupled state via facilitating the binding of L-arginine
to the heme site of eNOS [7, 9]. By contrast, BH2,o r
decreased ratio between BH4 and BH2, can result in the
uncoupled state of eNOS in that L-arginine is not bound to
the heme site and molecular oxygen is used as the substrate
to produce SO instead of NO (see Figure 9)[ 9–11, 13].
Therefore,inthenonischemicaorticsegments,wefoundthat
BH4 dose dependently increased NO release by promoting
eNOS coupling to produce more NO. By contrast, BH2 dose
dependently decreased NO release from aortic segments.
This trend of decreasing NO bioavailability by BH2 may
be because BH2 promotes eNOS uncoupling and facilitates
eNOS to produce SO instead of NO, which further quenches
NO via the formation of peroxynitrite [9].
Furthermore, we found similar eﬀects of BH4 and BH2
on NO release in femoral I/R. There was a slight decrease
in NO release (i.e., 6-7nM) from femoral veins in the I/R
limb compared to the sham limb in the saline control group.
By contrast, applying BH2 at the beginning of reperfusion
signiﬁcantly decreased NO release from 15 minutes and
throughout the rest of reperfusion. However, administration
of BH4 during the early reperfusion signiﬁcantly increased
NO release in comparison to BH2 treatment. This data
suggests that under I/R conditions, BH2 can further facilitate
eNOS uncoupling and further reduce NO release (i.e., in nM
concentration), whereas BH4 may help eNOS maintain the
coupled state and increase NO bioavailability. The in vivo
data from this study further supports in vitro data regarding
the role of BH4 and BH2 in eNOS coupling and uncoupling
[7, 11].
On the other hand, the eﬀects of BH4 and BH2 on H2O2
release in femoral I/R also demonstrate the contribution
of eNOS to the oxidative stress during reperfusion. It is
well known that H2O2 is a good indicator of oxidative
stress with a longer half-life (i.e., min) compared to SO
(i.e., sec) [12]. By directly measuring H2O2 release from
femoral veins in a rat femoral I/R model, we found that
H2O2 release from the I/R limb was signiﬁcantly higher
throughout the whole 45-minute reperfusion period com-
pared to the sham limb. This result provides direct evidence
to show the oxidative stress during the early reperfusion.
Furthermore, the administration of BH4 at the beginning of
reperfusion signiﬁcantly decreased H2O2 release. This data
suggests that maintenance of eNOS coupling by BH4 at the
start of reperfusion would help to attenuate the oxidative
stress.Advances in Pharmacological Sciences 9
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Figure 8: Histological assessment of total intravascular/inﬁltrated
PMNs and vascular adhered PMNs in isolated postreperfused
rat heart tissue from diﬀerent experimental groups. The total
intravascular/inﬁltrated PMNs in sham, I/R and I/R+PMN+BH4
(10μM) groups were signiﬁcantly reduced compared to that in
I/R+PMN group. Similarly, the vascular adhered PMNs in sham,
I/R, I/R+PMN+BH4 (5μM), and I/R+PMN+BH4 (10μM) groups
were also signiﬁcantly reduced compared to that in I/R+PMN
group. All values are expressed as mean ± SEM. Numbers of
samples are listed in the box with the bars. All drugs are in μM
concentrations. (∗∗P<. 01 from total intravascular/inﬁltrated
PMNs in I/R+PMN group; ##P<. 01 from vascular adhered PMNs
in I/R+PMN group).
By contrast, BH2 treatment during reperfusion main-
tained eNOS uncoupling, which is involved in mediat-
ing oxidative stress observed during the reperfusion. BH2
treatment resulted in the similar H2O2 increase to the
saline control throughout the reperfusion. It is possible
that increasing BH2 to BH4 ratio by itself may not make
a signiﬁcant contribution to enhance the oxidative stress
release compared to the saline control. As shown previously,
BH2 signiﬁcantly decreased NO release compared to saline
control during reperfusion, and this decrease was in the
range of 150 to 200nM, which is 10 to 15 times less the
amount of H2O2 change (i.e., micromolar range). It may be
plausible to speculate that signiﬁcant changes in NO release
in the nanomolar range can be observed with BH2 compared
to micromolar diﬀerences in H2O2 release. It is well known
that BH2 binds with equal aﬃnity as BH4 to the eNOS
oxygenase domain, and can displace BH4binding to facilitate
eNOS uncoupling [13]. To further promote additional eNOS
uncoupling, it would be necessary to increase eNOS activity,
such as with a protein kinase C (PKC) epsilon activator,
combined with additional BH2. Conversely, supplementing
BH4 under increased eNOS activity conditions may promote
additional eNOS coupling that otherwise would not be
observed under constitutive eNOS activity conditions [24].
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Figure 9: Schematic diagram of eNOS coupling and uncoupling.
BH4 binds to the heme oxygenase domain to promote L-arginine
substrate binding under eNOS coupling conditions. By contrast,
BH2 competes with BH4 at the heme oxygenase domain and
promotes molecular oxygen as substrate to produce superoxide and
eNOS uncoupling conditions (Adopted from [9]).
Theseexperimentswouldbeimportanttoidentifytheoverall
signiﬁcance of eNOS coupling/uncoupling contribution to
the restoration/impairment of blood vessel and organ func-
tion during reperfusion. Moreover, these experiments would
also identify a potential therapeutic tool that could be used
clinically in patients suﬀering from reperfusion injury by
ischemic-induced heart attack, coronary bypass/angioplasty
and organ transplantation.
4.3. The Role of BH4 and BH2 on Postreperfused Cardiac Func-
tion and PMN Adherence/Inﬁltration. Previous studies have
shown the eﬀectiveness of BH4 in restoring postreperfused
cardiac function [15]. However, these studies also gave BH4
prior to ischemia in addition to giving BH4 during the
reperfusion. By contrast, our studies only gave BH4 during
reperfusion. This point is important in that pretreatment10 Advances in Pharmacological Sciences
of tissue or organs prior to invasive surgical procedures
(i.e., organ transplantation) is not always a feasible option.
Therefore, in our study, BH4 is only given during the ﬁrst
5 minutes of reperfusion. We found that BH4 treatment
exerted partial restoration in postreperfused cardiac func-
tion, which is associated with signiﬁcantly less PMN vascular
adherence and tissue inﬁltration. The uniqueness of our
study is that we only evaluate the eﬀects of BH4 during
the reperfusion phase and clinically this approach may be
morefeasibleinthatBH4 couldbeadministeredimmediately
following coronary artery bypass and organ transplantation
procedures.
DespitethatBH4-treatedI/R+PMNheartsexhibited85%
postreperfused LVDP, +dP/dtmax only recovered by 71% and
was not signiﬁcantly increased compared to I/R+PMN con-
trol hearts. This may be due to saturation of eNOS coupling
with adding BH4 which may slow down the recovery of
postreperfused +dP/dtmax. By contrast, BH2-treated hearts
did not show any improvements in postreperfused heart
function suggesting that BH2 maintained eNOS uncoupling.
The postreperfused heart function in BH2-treated hearts was
similar to I/R+PMN control hearts, which suggest that BH2
didnotfurtherincreaseoxidativestressandisconsistentwith
the femoral I/R H2O2 release data. In future studies, we plan
to evaluate the role of eNOS uncoupling by increasing eNOS
activity combined with BH2 for any potential additive or
synergistic eﬀect. To test this hypothesis, increasing eNOS
activity during reperfusion with a PKC epsilon activator
combined with the same concentration of BH2 should result
in greater oxidative stress and lead to a more compromised
postreperfusedcardiacfunctionsincetheseconditionswould
promote more BH2 to interact with eNOS [25]. Conversely,
adding BH4 with increased eNOS activity (i.e., PKC epsilon
activator) would promote more BH4 to interact with eNOS
to produce more NO and optimally improve postreperfused
+dP/dtmax.
Alternatively, inhibiting eNOS only during reperfusion
with a PKC epsilon inhibitor would also attenuate oxidative
stress and restore postreperfused cardiac function regardless
of BH4-to-BH2 ratio as suggested from previous work show-
ing restoration of postreperfused cardiac function with PKC
epsilon inhibitor in an acute I/R and heart transplantation
models [12, 26]. In contrast to PKC epsilon inhibitor,
L-NAME does not inhibit SO release from eNOS [11]. L-
NAME competes with L-arginine at the heme site of the
eNOS oxygenase domain to inhibit the production of NO.
However, L-NAME will not inhibit the electron reduction
of molecular oxygen to SO at the site when BH2-to-BH4
ratio is increased [11]. It is conceivable that L-NAME would
therefore block the cardioprotective eﬀects of BH4 since it is
competing with L-arginine as a substrate as shown in Figures
5 and 6.
4.4. Signiﬁcance of Findings. In summary, this study further
supports the conception of BH4 promoting eNOS coupling
during I/R. By contrast, BH2 treatment may maintain the
eNOS uncoupled state during I/R and is associated with
compromised postreperfused cardiac function and increased
oxidative stress. Moreover, the connection of eNOS coupling
or uncoupling to I/R injury, especially during the reperfu-
sion, may encourage a novel optimal treatment strategy for
clinical cases.
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